Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled trial

Study timeline

• Publication added by Petros Isaakidis

  4th May 2023

  Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial Griesel, Rulan – F1000 Research Ltd (2021)
   
• Protocol added by Petros Isaakidis

  10th February 2020

  Dolutegravir_TB_phase_2_protocol_V1.2._MSF_ERB_REVISED_CLEAN.DOCX

  87.5 KB
   
• ERB documentation added by Petros Isaakidis

  10th February 2020

  18109_MSFERB_Amendment_Approval_23June2019.pdf

  683 KB
   
• ERB documentation added by Petros Isaakidis

  10th February 2020

  UCT_HREC_Protocol_amendment_approval_RADIANT-TB.pdf

  1.59 MB